REFERENCES
1. Song P, Fang Z, Wang H, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8:e721-9.
3. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16:203-12.
4. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23:3346.
5. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278:483-93.
6. Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7:131.
7. Mandaglio-Collados D, Marín F, Rivera-Caravaca JM. Peripheral artery disease: update on etiology, pathophysiology, diagnosis and treatment. Med Clin (Barc). 2023;161:344-50.
8. Papafaklis MI, Koros R, Tsigkas G, Karanasos A, Moulias A, Davlouros P. Reversal of atherosclerotic plaque growth and vulnerability: effects of lipid-modifying and anti-inflammatory therapeutic agents. Biomedicines. 2024;12:2435.
9. Liu Y, Lu K, Zhang R, et al. Advancements in the treatment of atherosclerosis: from conventional therapies to cutting-edge innovations. ACS Pharmacol Transl Sci. 2024;7:3804-26.
10. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276:618-32.
11. Saba JA, Liakath-Ali K, Green R, Watt FM. Translational control of stem cell function. Nat Rev Mol Cell Biol. 2021;22:671-90.
12. Abou-Saleh H, Zouein FA, El-Yazbi A, et al. The march of pluripotent stem cells in cardiovascular regenerative medicine. Stem Cell Res Ther. 2018;9:201.
13. Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9:17.
14. Kimbrel EA, Lanza R. Next-generation stem cells - ushering in a new era of cell-based therapies. Nat Rev Drug Discov. 2020;19:463-79.
15. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003;425:968-73.
16. Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng. 2023;:1-2.
17. Dinh PC, Paudel D, Brochu H, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun. 2020;11:1064.
18. Pan Y, Wu W, Jiang X, Liu Y. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: from mechanisms to therapy. Biomed Pharmacother. 2023;163:114817.
19. Zhang N, Xie X, Chen H, Chen H, Yu H, Wang JA. Stem cell-based therapies for atherosclerosis: perspectives and ongoing controversies. Stem Cells Dev. 2014;23:1731-40.
20. Dou Y, Chen Y, Zhang X, et al. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Biomaterials. 2017;143:93-108.
21. Ling H, Guo Z, Tan L, Cao Q, Song C. Stem cell-derived exosomes: role in the pathogenesis and treatment of atherosclerosis. Int J Biochem Cell Biol. 2021;130:105884.
23. Li H, Zhang J, Tan M, et al. Exosomes based strategies for cardiovascular diseases: opportunities and challenges. Biomaterials. 2024;308:122544.
24. Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci. 2021;8:2002944.
25. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. 2019;8:1605.
26. Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015;30:580-9.
27. Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary fibrosis. Stem Cell Res Ther. 2022;13:492.
28. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6:2173-85.
29. Slukvin II, Kumar A. The mesenchymoangioblast, mesodermal precursor for mesenchymal and endothelial cells. Cell Mol Life Sci. 2018;75:3507-20.
30. Li B, Cheng Y, Yu S, et al. Human umbilical cord-derived mesenchymal stem cell therapy ameliorates nonalcoholic fatty liver disease in obese type 2 diabetic mice. Stem Cells Int. 2019;2019:8628027.
31. Li Y, Shi G, Liang W, et al. Allogeneic Adipose-derived mesenchymal stem cell transplantation alleviates atherosclerotic plaque by inhibiting Ox-LDL uptake, inflammatory reaction and endothelial damage in rabbits. Cells. 2023;12:1936.
32. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109:1292-8.
33. Shi H, Liang M, Chen W, et al. Human induced pluripotent stem cellderived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses. Mol Med Rep. 2018;17:1461-8.
34. Lin Y, Zhu W, Chen X. The involving progress of MSCs based therapy in atherosclerosis. Stem Cell Res Ther. 2020;11:216.
35. Li X, Deng Y, Zhao S, Zhang D, Chen Q. Injection of hTERT-transduced endothelial progenitor cells promotes beneficial aortic changes in a high-fat dietary model of early atherosclerosis. Cardiology. 2017;136:230-40.
36. Lin YL, Yet SF, Hsu YT, Wang GJ, Hung SC. Mesenchymal stem cells ameliorate atherosclerotic lesions via restoring endothelial function. Stem Cells Transl Med. 2015;4:44-55.
38. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med. 2017;95:1153-65.
39. Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024;21:487-97.
40. Bloom SI, Islam MT, Lesniewski LA, Donato AJ. Mechanisms and consequences of endothelial cell senescence. Nat Rev Cardiol. 2023;20:38-51.
41. Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924-67.
42. Grego A, Fernandes C, Fonseca I, et al. Endothelial dysfunction in cardiovascular diseases: mechanisms and in vitro models. Mol Cell Biochem. 2025;480:4671-95.
43. Salvolini E, Orciani M, Vignini A, Mattioli-Belmonte M, Mazzanti L, Di Primio R. Skin-derived mesenchymal stem cells (S-MSCs) induce endothelial cell activation by paracrine mechanisms. Exp Dermatol. 2010;19:848-50.
44. Liu Y, Chen J, Liang H, et al. Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling. Stem Cell Res Ther. 2022;13:258.
45. Wang J, Meng S, Chen Y, et al. MSC-mediated mitochondrial transfer promotes metabolic reprograming in endothelial cells and vascular regeneration in ARDS. Redox Rep. 2025;30:2474897.
46. Dabravolski SA, Popov MA, Utkina AS, et al. Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment. Mol Cell Biochem. 2025;480:4647-70.
47. Gao H, Yu Z, Li Y, Wang X. miR-100-5p in human umbilical cord mesenchymal stem cell-derived exosomes mediates eosinophilic inflammation to alleviate atherosclerosis via the FZD5/Wnt/β-catenin pathway. Acta Biochim Biophys Sin. 2021;53:1166-76.
48. Werner N, Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med. 2006;10:318-32.
49. Liu Z, Ding X, Fang F, et al. Higher numbers of circulating endothelial progenitor cells in stroke patients with intracranial arterial stenosis. BMC Neurol. 2013;13:161.
50. Altabas V, Biloš LSK. The role of endothelial progenitor cells in atherosclerosis and impact of anti-lipemic treatments on endothelial repair. Int J Mol Sci. 2022;23:2663.
51. Yang J, Lu Y, Zhao J, et al. Reinvesting the cellular properties of human amniotic epithelial cells and their therapeutic innovations. Front Immunol. 2024;15:1466529.
52. Miki T. Stem cell characteristics and the therapeutic potential of amniotic epithelial cells. Am J Reprod Immunol. 2018;80:e13003.
53. Qiu C, Ge Z, Cui W, Yu L, Li J. Human amniotic epithelial stem cells: a promising seed cell for clinical applications. Int J Mol Sci. 2020;21:7730.
54. Miki T. A rational strategy for the use of amniotic epithelial stem cell therapy for liver diseases. Stem Cells Transl Med. 2016;5:405-9.
55. Tan B, Yuan W, Li J, et al. Therapeutic effect of human amniotic epithelial cells in murine models of Hashimoto’s thyroiditis and systemic lupus erythematosus. Cytotherapy. 2018;20:1247-58.
56. Yang PJ, Zhao XY, Kou YH, et al. Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease. Acta Pharmacol Sin. 2024;45:2339-53.
57. Fang SM, Du DY, Li YT, et al. Allogeneic bone marrow mesenchymal stem cells transplantation for stabilizing and repairing of atherosclerotic ruptured plaque. Thromb Res. 2013;131:e253-7.
58. Taraballi F, Pastò A, Bauza G, Varner C, Amadori A, Tasciotti E. Immunomodulatory potential of mesenchymal stem cell role in diseases and therapies: a bioengineering prospective. J Immunol Regen Med. 2019;4:100017.
59. Siew WS, Tang YQ, Kong CK, et al. Harnessing the potential of CRISPR/Cas in atherosclerosis: disease modeling and therapeutic applications. Int J Mol Sci. 2021;22:8422.
60. Oostveen RF, Khera AV, Kathiresan S, et al. New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing. Arterioscler Thromb Vasc Biol. 2023;43:1081-92.
61. Bagno LL, Carvalho D, Mesquita F, et al. Sustained IGF-1 secretion by adipose-derived stem cells improves infarcted heart function. Cell Transplant. 2016;25:1609-22.
62. Choi JS, Jeong IS, Han JH, Cheon SH, Kim SW. IL-10-secreting human MSCs generated by TALEN gene editing ameliorate liver fibrosis through enhanced anti-fibrotic activity. Biomater Sci. 2019;7:1078-87.
63. Lin YK, Hsiao LC, Wu MY, et al. PD-L1 and AKT overexpressing adipose-derived mesenchymal stem cells enhance myocardial protection by upregulating CD25+ T cells in acute myocardial infarction rat model. Int J Mol Sci. 2023;25:134.
64. Chuang ST, Stein JB, Nevins S, et al. Enhancing CAR macrophage efferocytosis via surface engineered lipid nanoparticles targeting LXR signaling. Adv Mater. 2024;36:2308377.
65. Tan H, Li W, Pang Z, et al. Genetically engineered macrophages Co-loaded with CD47 inhibitors synergistically reconstruct efferocytosis and improve cardiac remodeling post myocardial ischemia reperfusion injury. Adv Healthc Mater. 2024;13:2303267.
66. Liu H, Wu S, Lee H, et al. Polymer-functionalized mitochondrial transplantation to plaque macrophages as a therapeutic strategy targeting atherosclerosis. Adv Ther. 2022;5:2100232.
67. Jiang Y, Yu M, Song ZF, Wei ZY, Huang J, Qian HY. Targeted delivery of mesenchymal stem cell-derived bioinspired exosome-mimetic nanovesicles with platelet membrane fusion for atherosclerotic treatment. Int J Nanomedicine. 2024;19:2553-71.
68. Luo L, Tang J, Nishi K, et al. Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. Circ Res. 2017;120:1768-75.
69. Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev. 2021;178:113961.
70. Dixson AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat Rev Mol Cell Biol. 2023;24:454-76.
71. Sanz-Ros J, Romero-García N, Mas-Bargues C, et al. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. Sci Adv. 2022;8:eabq2226.
72. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
73. Yin Y, Chen H, Wang Y, Zhang L, Wang X. Roles of extracellular vesicles in the aging microenvironment and age-related diseases. J Extracell Vesicles. 2021;10:e12154.
74. Chen YT, Yuan HX, Ou ZJ, Ou JS. Microparticles (Exosomes) and Atherosclerosis. Curr Atheroscler Rep. 2020;22:23.
75. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14:259-72.
76. Li J, Wen T, Li X, et al. Harnessing extracellular vesicles to tame inflammation: a new strategy for atherosclerosis therapy. Front Immunol. 2025;16:1625958.
77. Adamiak M, Sahoo S. Exosomes in myocardial repair: advances and challenges in the development of next-generation therapeutics. Mol Ther. 2018;26:1635-43.
78. Yuan Y, Du W, Liu J, et al. Stem cell-derived exosome in cardiovascular diseases: macro roles of micro particles. Front Pharmacol. 2018;9:547.
79. Wendt S, Goetzenich A, Goettsch C, et al. Evaluation of the cardioprotective potential of extracellular vesicles - a systematic review and meta-analysis. Sci Rep. 2018;8:15702.
80. Li L, Wang H, Zhang J, Chen X, Zhang Z, Li Q. Effect of endothelial progenitor cell-derived extracellular vesicles on endothelial cell ferroptosis and atherosclerotic vascular endothelial injury. Cell Death Discov. 2021;7:235.
81. Xiao X, Xu M, Yu H, et al. Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src. Signal Transduct Target Ther. 2021;6:354.
82. Xing X, Li Z, Yang X, et al. Adipose-derived mesenchymal stem cells-derived exosome-mediated microRNA-342-5p protects endothelial cells against atherosclerosis. Aging. 2020;12:3880-98.
83. Lu W, Li X, Wang Z, et al. Mesenchymal stem cell-derived extracellular vesicles accelerate diabetic wound healing by inhibiting NET-induced ferroptosis of endothelial cells. Int J Biol Sci. 2024;20:3515-29.
84. Li J, Xue H, Li T, et al. Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE-/- mice via miR-let7 mediated infiltration and polarization of M2 macrophage. Biochem Biophys Res Commun. 2019;510:565-72.
85. Ma J, Chen L, Zhu X, Li Q, Hu L, Li H. Mesenchymal stem cell-derived exosomal miR-21a-5p promotes M2 macrophage polarization and reduces macrophage infiltration to attenuate atherosclerosis. Acta Biochim Biophys Sin. 2021;53:1227-36.
86. de Couto G, Gallet R, Cambier L, et al. Exosomal MicroRNA transfer into macrophages mediates cellular postconditioning. Circulation. 2017;136:200-14.
87. Yang F, Wu Y, Chen Y, et al. Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis. JHEP Rep. 2023;5:100746.
88. Liu C, Su C. Design strategies and application progress of therapeutic exosomes. Theranostics. 2019;9:1015-28.
89. Zhu Y, Liao ZF, Mo MH, Xiong XD. Mesenchymal stromal cell-derived extracellular vesicles for vasculopathies and angiogenesis: therapeutic applications and optimization. Biomolecules. 2023;13:1109.
90. Ramaraju H, Miller SJ, Kohn DH. Dual-functioning peptides discovered by phage display increase the magnitude and specificity of BMSC attachment to mineralized biomaterials. Biomaterials. 2017;134:1-12.
91. Nakamura Y, Kita S, Tanaka Y, et al. Adiponectin stimulates exosome release to enhance mesenchymal stem-cell-driven therapy of heart failure in mice. Mol Ther. 2020;28:2203-19.
92. Wang H, Bai Z, Qiu Y, et al. Empagliflozin-pretreated MSC-derived exosomes enhance angiogenesis and wound healing via PTEN/AKT/VEGF pathway. Int J Nanomedicine. 2025;20:5119-36.
93. Fathi E, Farahzadi R, Sheikhzadeh N. Immunophenotypic characterization, multi-lineage differentiation and aging of zebrafish heart and liver tissue-derived mesenchymal stem cells as a novel approach in stem cell-based therapy. Tissue Cell. 2019;57:15-21.
94. Wiklander OP, Nordin JZ, O’Loughlin A, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4:26316.
95. Li J, Sun S, Zhu D, et al. Inhalable stem cell exosomes promote heart repair after myocardial infarction. Circulation. 2024;150:710-23.
96. Hu S, Li Z, Shen D, et al. Exosome-eluting stents for vascular healing after ischaemic injury. Nat Biomed Eng. 2021;5:1174-88.
97. Lin Y, Yan M, Bai Z, et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnology. 2022;20:432.
98. Zheng J, Li Y, Ge X, et al. Devouring atherosclerotic plaques: the engineered nanorobot rousing macrophage efferocytosis by a two-pronged strategy. Adv Funct Mater. 2025;35:2415477.
99. Yin M, Lin J, Yang M, et al. Platelet membrane-cloaked selenium/ginsenoside Rb1 nanosystem as biomimetic reactor for atherosclerosis therapy. Colloids Surf B Biointerfaces. 2022;214:112464.
100. Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118-21.
101. Modery-Pawlowski CL, Kuo HH, Baldwin WM, Sen Gupta A. A platelet-inspired paradigm for nanomedicine targeted to multiple diseases. Nanomedicine. 2013;8:1709-27.
102. Xie L, Chen J, Hu H, et al. Engineered M2 macrophage-derived extracellular vesicles with platelet membrane fusion for targeted therapy of atherosclerosis. Bioact Mater. 2024;35:447-60.
103. Hu S, Wang X, Li Z, et al. Platelet membrane and stem cell exosome hybrids enhance cellular uptake and targeting to heart injury. Nano Today. 2021;39:101210.
104. Wang L, Wang D, Ye Z, Xu J. Engineering extracellular vesicles as delivery systems in therapeutic applications. Adv Sci. 2023;10:2300552.
105. Malle MG, Song P, Löffler PMG, et al. Programmable RNA loading of extracellular vesicles with toehold-release purification. J Am Chem Soc. 2024;146:12410-22.
106. Li Z, Zhao P, Zhang Y, et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics. 2021;11:2953-65.
107. Zou J, Cui W, Deng N, et al. Fate reversal: Exosome-driven macrophage rejuvenation and bacterial-responsive drug release for infection immunotherapy in diabetes. J Control Release. 2025;382:113730.
108. Du Y, Wang H, Yang Y, et al. Extracellular Vesicle mimetics: preparation from top-down approaches and biological functions. Adv Healthc Mater. 2022;11:2200142.
109. Ohta H, Liu X, Maeda M. Autologous adipose mesenchymal stem cell administration in arteriosclerosis and potential for anti-aging application: a retrospective cohort study. Stem Cell Res Ther. 2020;11:538.
110. Saad A, Dietz AB, Herrmann SMS, et al. Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease. J Am Soc Nephrol. 2017;28:2777-85.
111. Marei HE. Stem cell therapy: a revolutionary cure or a pandora’s box. Stem Cell Res Ther. 2025;16:255.
112. Zhu Y, Ge J, Huang C, Liu H, Jiang H. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics. Theranostics. 2021;11:5675-85.
113. Zhou W, Lin J, Zhao K, et al. Single-cell profiles and clinically useful properties of human mesenchymal stem cells of adipose and bone marrow origin. Am J Sports Med. 2019;47:1722-33.
114. Sato Y, Bando H, Di Piazza M, et al. Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider. Cytotherapy. 2019;21:1095-111.
115. Emini Veseli B, Perrotta P, De Meyer GRA, et al. Animal models of atherosclerosis. Eur J Pharmacol. 2017;816:3-13.
116. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012;111:245-59.
117. Qu Q, Fu B, Long Y, Liu ZY, Tian XH. Current strategies for promoting the large-scale production of exosomes. Curr Neuropharmacol. 2023;21:1964-79.
